Cargando…

Role of hepatic resection in patients with intermediate‐stage hepatocellular carcinoma: A multicenter study from Japan

Transarterial chemoembolization (TACE) is recommended for patients with intermediate‐stage (Barcelona Clinic Liver Cancer criteria B [BCLC‐B]) hepatocellular carcinoma (HCC). However, patients with BCLC‐B HCC can differ in background factors related to hepatic function, as well as tumor size and num...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tada, Toshifumi, Kumada, Takashi, Toyoda, Hidenori, Tsuji, Kunihiko, Hiraoka, Atsushi, Itobayashi, Ei, Nouso, Kazuhiro, Kariyama, Kazuya, Ishikawa, Toru, Hirooka, Masashi, Hiasa, Yoichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497930/ https://www.ncbi.nlm.nih.gov/pubmed/28406546 http://dx.doi.org/10.1111/cas.13257

Ejemplares similares

Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma
por: Kariyama, Kazuya, et al.
Publicado: (2019)

Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality
por: Hiraoka, Atsushi, et al.
Publicado: (2023)

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2018)

The prognosis of elderly patients with hepatocellular carcinoma: A multi‐center 19‐year experience in Japan
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2019)

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2021)

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2022)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022)

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study
por: Tada, Toshifumi, et al.
Publicado: (2022)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
por: Nouso, Kazuhiro, et al.
Publicado: (2023)

Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
por: Tada, Toshifumi, et al.
Publicado: (2022)

The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study
por: Tada, Toshifumi, et al.
Publicado: (2020)

Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation
por: Hiraoka, Atsushi, et al.
Publicado: (2017)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
por: Tanaka, Kazunari, et al.
Publicado: (2023)

Combination therapy of transcatheter arterial chemoembolization with axitinib for the treatment of inoperable hepatocellular carcinoma
por: Nouso, Kazuhiro, et al.
Publicado: (2020)

Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response
por: Toyoda, Hidenori, et al.
Publicado: (2021)

Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan
por: Toyoda, Hidenori, et al.
Publicado: (2011)

Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan
por: Toyoda, Hidenori, et al.
Publicado: (2019)

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
por: Hirooka, Masashi, et al.
Publicado: (2018)

Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
por: Tada, Toshifumi, et al.
Publicado: (2017)

Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era
por: Nakamura, Yoshiko, et al.
Publicado: (2023)

Clinical Usefulness of Surgical Resection Including the Complementary Use of Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma
por: Ohama, Hideko, et al.
Publicado: (2022)

Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy
por: Toyoda, Hidenori, et al.
Publicado: (2014)

Molecular Evolution and Phylodynamics of Acute Hepatitis B Virus in Japan
por: Lin, Serena Y. C., et al.
Publicado: (2016)

AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy
por: Watanabe, Takao, et al.
Publicado: (2021)

Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus
por: Tachi, Yoshihiko, et al.
Publicado: (2015)

Natural history of liver‐related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model
por: Tada, Toshifumi, et al.
Publicado: (2019)

Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus
por: Kumada, Takashi, et al.
Publicado: (2021)

Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment
por: Chuma, Makoto, et al.
Publicado: (2022)

Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals
por: Watanabe, Takao, et al.
Publicado: (2023)

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2022)

High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma
por: Kumada, Takashi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t9smk9ko8l15gngjlind2rvq7d